

<p>Informazione Regolamentata n. 0957-29-2026</p>	<p>Data/Ora Inizio Diffusione 20 Marzo 2026 18:33:35</p>	<p>Euronext Milan</p>
---	--	-----------------------

Societa' : DIASORIN

Utenza - referente : DIASORINN01 - Ulisse Spada - Valerio Vaccarone

Tipologia : REGEM

Data/Ora Ricezione : 20 Marzo 2026 18:33:35

Data/Ora Inizio Diffusione : 20 Marzo 2026 18:33:35

Oggetto : Diasorin S.p.A. - Update Calendar of Corporate Events 2026

Testo del comunicato

See in attachment.

DIASORIN S.P.A. – UPDATE 2026 ANNUAL CALENDAR OF CORPORATE EVENTS*

Saluggia, March 20, 2026 – Updating the notice published on December 22, 2025, please find below the the new scheduled date for the approval of the First Quarter 2026 results approval.

Board of Directors

May 8, 2026	First Quarter 2026 results approval
July 31, 2026	Half-Yearly Financial Report approval
November 6, 2026	Third Quarter 2026 results approval

Shareholders' Meeting

April 29, 2026	Annual General Meeting for: (i) 2025 Statutory Financial Statements approval; (ii) Report on the remuneration policy and fees paid approval.
-----------------------	---

* Indicative dates subject to change. Any changes will be communicated without delay.

The conference call for the presentation of the financials results to the investors will take place, as in the past, on the same day of the approval by the Board of Directors. The timing will be communicated as soon as scheduled.

PRESS RELEASE ○○○

About DiaSorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:**INVESTOR RELATIONS****Riccardo Fava**

Corporate VP Communication, ESG & Investor Relations

riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Senior Analyst

eugenia.ragazzo@diasorin.it

